Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder
Xylinas E1, Kluth LA1, Lotan Y2, Daneshmand S3, Rieken M1, Karakiewicz PI4, Shariat SF5. Urol Oncol. 2013 Dec 11. pii: S1078-1439(13)00258-5. doi: 10.1016/j.urolonc.2013.06.009. [Epub ahead of print]

Author information

1Department of Urology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY. 2Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. 3USC Institute of Urology, Norris Comprehensive Cancer Center, Los Angeles, CA. 4Department of Urology, University of Montreal Health Center, Montreal, Canada. 5Department of Urology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY; Division of Medical Oncology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: sfshariat@gmail.com. < p>

Abstract

OBJECTIVES: Urothelial carcinoma of the bladder (UCB) is a highly heterogeneous malignancy that causes significant morbidity and mortality. Standard pathologic features (stage, grade, and nodal status) are insufficient to predict accurately a patient's outcome. Biomarkers could help clinicians provide individualized prognostications and allow risk-stratified clinical decision making regarding surgical and medical treatment. This review summarizes the existing tissue- and blood-based biomarkers in UCB.

MATERIAL AND METHODS: A PubMed/Medline search was conducted to identify original articles regarding molecular biomarkers and UCB. Searches were limited to papers published in English. Keywords included urothelial carcinoma, bladder cancer, transitional cell, biomarker, marker, staining, cystectomy, recurrence or progression, survival, prediction, and prognosis.

RESULTS: The articles with the highest level of evidence were selected and reviewed, with the consensus of all the authors of this paper. CONCLUSIONS: There is no doubt that a panel of biomarkers would eventually improve our clinical decision making regarding treatment and follow-up. However, to date, no biomarker panel is yet validated for daily clinical practice.